Package Leaflet: Information for the Patient
Dezipar 10 mg/10 mg Film-Coated Tablets
Donepezil Hydrochloride/Memantine Hydrochloride
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Contents of the pack and further information
What Dezipar is used for
Dezipar is indicated as a replacement treatment in adult patients with moderate to severe Alzheimer's disease who are adequately controlled with a stable daily dose of 10 mg of donepezil and 10 mg of memantine, taken as a free combination.
How Dezipar works
Dezipar is a combination of an acetylcholinesterase inhibitor (donepezil) and an NMDA receptor antagonist (memantine). Acetylcholinesterase inhibitors, such as donepezil, increase the levels of a substance related to memory (acetylcholine) in the brain by reducing the breakdown of this substance. Memantine hydrochloride, by inhibiting the activity of NMDA receptors, improves the transmission of nerve signals and memory.
Do not take Dezipar
Warnings and precautions
Consult your doctor before starting to take Dezipar if you have or have had:
In the above situations, treatment should be carefully supervised, and your doctor should regularly reassess the clinical benefit of Dezipar.
If you have kidney failure (kidney problems), your doctor should closely monitor your kidney function and, if necessary, adjust the dose of memantine.
If you have renal tubular acidosis (RTA, excess of acid-producing substances in the blood due to kidney dysfunction) or severe urinary tract infections (urinary tract), your doctor may need to adjust the dose of the medication.
Inform your doctor if you have any liver disease. Dezipar can be used in patients with mild to moderate liver failure. Patients with severe liver failure should not take Dezipar.
You should avoid taking Dezipar with other acetylcholinesterase inhibitors and other agonists or antagonists of the cholinergic system, with medications such as amantadine (for the treatment of Parkinson's disease), ketamine (a medication generally used to produce anesthesia), dextromethorphan (a medication for the treatment of cough), and other NMDA antagonists.
Children and adolescents
Dezipar is not recommended for use in children and adolescents under 18 years of age.
Other medications and Dezipar
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, especially if you are taking any of the following medications:
In case of surgical intervention with general anesthesia, you should inform your doctor that you are taking Dezipar, as this may affect the amount of anesthetic needed.
If you are hospitalized, inform your doctor that you are taking Dezipar.
Taking Dezipar with food, drinks, and alcohol
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g., from a normal diet to a strict vegetarian diet).
This medication should not be taken with alcohol, as alcohol may alter the effect of this medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Do not take Dezipar if you are pregnant or think you may be pregnant.
Breastfeeding
Women taking Dezipar should not breastfeed.
Driving and using machines
Your doctor will inform you if your illness allows you to drive and use machines safely.
Also, Dezipar may alter your reaction ability, so driving or operating machines may be inappropriate.
Follow the administration instructions of this medication exactly as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Dosage
The recommended dose in adult and elderly patients is 1 tablet administered once a day.
Dosage for patients with renal impairment
If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should periodically monitor your kidney function.
Dosage for patients with hepatic impairment
If you have liver failure (a disease that affects the liver) of mild or moderate severity, you can take this medication. Patients with severe liver failure should not take this medication.
Use in children and adolescents
Dezipar is not recommended for use in children and adolescents under 18 years of age.
Method of administration and route of administration
It is administered orally, with a little water, at night immediately before bedtime. If you have abnormal dreams, nightmares, or difficulty sleeping (see section 4), your doctor may recommend that you take Dezipar in the morning. The tablets can be taken with or without food.
The score line should not be used to divide the tablet.
Duration of treatment
Continue taking this medication as long as it is beneficial for you. Your doctor should evaluate the effects of your treatment periodically.
If you take more Dezipar than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
The symptoms of overdose may include nausea, vomiting, drooling, sweating, decreased heart rate, low blood pressure (dizziness or fainting when standing up), breathing problems, loss of consciousness, and seizures. You may experience an increase in the symptoms described in section 4 "Possible side effects".
If you forget to take Dezipar
If you realize that you have forgotten to take your dose, wait and take the next dose at the usual time.
Do not take a double dose to make up for forgotten doses.
If you stop taking Dezipar
Do not stop taking this medication unless your doctor tells you to. If you stop taking this medication, the benefits of treatment will gradually disappear.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone gets them.
The following serious side effectshave been reported only with the use of donepezil as an individual component. You should inform your doctor immediately if you notice any of these serious side effects, as you may need urgent medical treatment:
The following side effects are described for the individual components, donepezil (5-10 mg) or memantine (10-20 mg):
Donepezil
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Frequency not known (frequency cannot be estimated from available data)
Memantine
In general, side effects are mild to moderate.
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (frequency cannot be estimated from available data)
Alzheimer's disease has been associated with depression, suicidal ideation, and suicide. These events have been reported in patients treated with memantine.
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the national reporting system: Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Dezipar
Appearance of the product and contents of the pack
Dezipar 10 mg/10 mg film-coated tablets are presented in the form of blue, circular (approximately 9 mm in diameter), and convex film-coated tablets.
The tablets are available in PVC/PE.EVOH.PE/PCTFE-Aluminum blister packs containing 28 tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder
Zambon S.A.U.
C/Maresme, 5. Polígono Can Bernades-Subirà
08130 Sta. Perpètua de la Mogoda – Barcelona
Spain
Manufacturer
Atlantic Pharma – Produções Farmacêuticas, S.A.
Rua da Tapada Grande, nº2, Abrunheira
2710-228 Sintra
Portugal
Date of the last revision of this package leaflet: March 2023
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).